Clinical Significance of Anticardiolipin IgM 18.26
An anticardiolipin IgM level of 18.26 is likely a low-positive result that requires repeat testing in 12 weeks and concurrent evaluation of lupus anticoagulant (LA) and anti-β2GPI antibodies to determine clinical significance, as isolated IgM positivity has limited clinical relevance for thrombotic risk but may be relevant for pregnancy morbidity.
Interpretation of This Result
The value of 18.26 falls into what is typically considered a low-positive range for anticardiolipin IgM antibodies. According to the most recent 2025 ISTH-SSC guidance, results should be interpreted according to local laboratory cutoff values set at the >99th percentile of normal controls 1. Your result appears to be above the cutoff but in the lower range of positivity.
Key Considerations for Low-Positive IgM Results:
IgM isotype is less clinically relevant than IgG: The 2025 ISTH guidance explicitly states that "single IgM is regarded as less clinically relevant" and that "IgG isotype is regarded as clinically more relevant rather than IgM" 1
Isolated IgM has contradictory thrombotic risk: A 2020 multicenter study of 1008 patients found that isolated IgM was rare in thrombotic APS (3.5-5.4%) and that IgM positivity was not independently associated with thrombosis in multivariate analysis 2. Similarly, a 2016 systematic review found "more significant correlations with thrombosis for the IgG than for the IgM isotype" 3
May be relevant for pregnancy morbidity: The same 2020 study found isolated IgM more frequent in obstetric APS (5.7-12.3%) and that IgM positivity was independently associated with pregnancy morbidity 2
Mandatory Next Steps
1. Complete the Antiphospholipid Antibody Panel
You must test concurrently for:
- Lupus anticoagulant (LA) - the strongest predictor of thrombotic risk
- Anti-β2GPI IgG and IgM
- Anticardiolipin IgG (if not already done)
The 2025 ISTH guidance strongly recommends "concurrent testing for LA, aCL IgG and IgM, and aβ2GPI IgG and IgM" 1. Testing only one antibody is insufficient for risk stratification.
2. Repeat Testing at 12 Weeks
Confirmation testing is mandatory because transient antibodies occur with infections and drugs 1. The diagnosis of APS requires "two consecutive aPL tests to be positive at least 12 weeks apart" with the same antibody remaining positive 1.
A 1996 study found that 9.3% of patients with low-positive IgG or IgM antibodies converted to high-positive or LA-positive on retesting, and half of these converters developed clinical complications 4.
3. Assess the Antibody Profile
The clinical significance depends entirely on the complete antibody profile:
- Triple positivity (LA + aCL + aβ2GPI): Highest risk for thrombosis and pregnancy complications 1
- Double positivity (aCL and aβ2GPI with concordant isotype, LA negative): 86% presented with APS clinical criteria 1
- Isolated aCL IgM: Lowest clinical significance, with contradictory thrombotic risk data 1
Clinical Context Matters
If This Patient Has:
Thrombotic events: Isolated IgM has limited diagnostic value for thrombotic APS. A 2012 review confirmed that "LA is a stronger risk factor for both arterial and venous thrombosis compared with aCL and aβ2GPI" 5. Complete the panel focusing on LA and IgG antibodies.
Pregnancy complications: IgM antibodies have more relevance here. The 2020 multicenter study supports "testing for aCL and aβ2GPI IgM in women suspected of obstetric APS" 2.
No clinical symptoms: Low-positive IgM alone does not confer increased risk beyond baseline medical history 4. However, repeat testing is warranted if new symptoms develop.
Critical Pitfalls to Avoid
Do not diagnose APS based on a single test: Persistent positivity (≥12 weeks apart) is required 1
Do not ignore assay variability: Results near the cutoff value should be interpreted cautiously due to assay imprecision (acceptable maximum 10%) 1. A small difference around the cutoff may influence classification.
Do not assume all positive results are pathogenic: Isolated aCL IgM may reflect antibodies directed against cardiolipin itself rather than β2GPI-dependent antibodies, which have disputed clinical relevance 1
Consider transient causes: Infections and certain drugs can cause transient antibody positivity 1
Risk Stratification Algorithm
Complete antibody panel → Assess profile:
- If LA positive or triple positive → High risk, repeat at 12 weeks
- If double positive (concordant isotype) → Moderate-high risk, repeat at 12 weeks
- If isolated IgM only → Low risk for thrombosis, may be relevant for pregnancy morbidity, repeat at 12 weeks
- If negative on other tests → Very low clinical significance, repeat only if new symptoms develop
The 2025 ISTH guidance emphasizes that "persistent medium/high titer (>99th percentile) is of utmost importance" when only one antibody is positive 1.